SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity

Fan Yin1, Fan Feng2, Lei Wang3, Xiaoning Wang4, Zongwei Li3 and Yu Cao5

Abstract

Lipid metabolism that correlates tightly to the glucose metabolic regulation in malignant cells includes hepatocellular carcinoma (HCC) cells. The transcription factor Sterol Regulatory Element Binding Protein 1 (SREBP-1), a regulator of fatty acid synthesis, has been shown to pivotally regulate the proliferation and metastasis of HCC cells. However, the intrinsic mechanism by which SREBP-1 regulates the survival of HCC cells remains unclear. In this study, among HCC patients who had dismal responses to Sorafenib, a high SREBP-1 level was found in the tumors and correlated to poor survival. This observation suggested the negative role of SREBP-1 in clinical HCC prognosis. Our mechanistical studies reveal that the inhibition of SREBP-1 via its inhibitor Betulin suppresses cellular glucose metabolism. In addition to the reduced glycolytic activity, a thwarted metastatic potential was observed in HCC cells upon Betulin administration. Moreover, our data show that SREBP-1 inhibition facilitated the antitumor effects of Sorafenib on HCC cells and xenograft tumors.

Introduction

In China, the population of chronic asymptomatic Hepatitis B Virus (HBV) infection-associated patients exceeds 80 million1–3. Hepatocellular carcinoma (HCC) is the final malignant disease developed from liver lesions such as HBV infection; it is a fatal threat to life and an increasing burden to the public medical service4–6. Thus, it is urgent to develop effective therapeutic approaches for HCC. At present, kinase inhibitors represented by Sorafenib are the major treatment choice for advanced HCC patients7,8. As an oral administrative multi-target protein-kinase inhibitor, Sorafenib downregulates the activity of RTKs (receptor protein tyrosine kinases include vascular endothelial growth factor receptor 2/3 [VEGFR-2/3], the hepatocyte factor receptor [c-Kit], Fms-like tyrosine kinase [FLT-3], and platelet-derived growth factor receptor-β [PDGFR-β]) and inhibits the proliferation, metastasis, and angiogenesis of HCC cells9–11. The randomized controlled phase III trials, represented by the SHARP (Sorafenib HCC Assessment Randomized Protocol) clinical trial, have shown that Sorafenib significantly prolongs the median survival of patients compared with the placebo group, making it a first-line antitumor agent for advanced HCC treatment12–15. However, the sensitivity of Sorafenib in HCC patients varies, with a large proportion finally developed for Sorafenib resistance unexpectedly16,17. Thus, it is of great importance to discover a new drug and/or to develop a novel therapeutic strategy that increases the efficacy of Sorafenib.

Cellular metabolisms related to ATP production in malignant cells are more active than normal cells18. HCC cells have exaggerated glucose uptake capability for their intensive anaerobic glycolysis which provides them...
enough energy to survive in harsh tumor microenvironment\textsuperscript{19,20}. The chemoresistance of HCC cells closely correlates to the cellular metabolism; through the overwhelming anaerobic glycolytic activity, the accommodation of metabolites and the enhanced epithelial–mesenchymal transition (EMT) afterward take place\textsuperscript{21,22}. Thus, glucose metabolism is a potential target of developing antagonistic therapy for chemoresistance.

It is known that 60% of the carbons in glucose are used for fatty acid synthesis, and lipid metabolism also plays vital roles in regulating glucose uptake and glycolytic activities\textsuperscript{23}. SREBP-1 is a core transcription factor in lipid metabolism; it induces the transcription of a series of genes involved in fatty acid and triglyceride synthesis\textsuperscript{24}. Inhibition of the activity of SREBP-1 decreases the synthesis and accommodation of fat and impeded the glucose uptake\textsuperscript{25–27}. Betulin belongs to lupane-type pentacyclic triterpenoids, which are widely found in plants such as Pulsatilla chinensis (Bunge) Regel; they have multiple biological functions, including antitumor activity\textsuperscript{28–30}. Betulin directly binds to the SCAP (SREBP cleavage-activating protein) to inhibit the cleavage and activation of SREBP-1\textsuperscript{31,32}. In the present study, we performed gene expression analysis on HCC patients after Sorafenib treatment, and found that the high SREBP-1 expression correlates to a poor clinical outcome. Mechanistically, our results indicate that SREBP-1 inhibition represses the cellular glycolytic activity of HCC cells, and restricts the metastasis of those malignant cells both in vitro and in vivo. We also found that Betulin works synergistically with Sorafenib on s.c. and in situ HCC tumors. Our study suggests that the SREBP-1 inhibitor and Sorafenib combination can be a novel therapeutic option for advanced HCC treatment.

Materials and methods
Cell lines and reagents
The hepatic cell lines: non-tumor cell line L-02, HCC cell lines HepG2, Hu7, SMMC-7721, and BEL-7402, a lowly aggressive HCC cell line (MHCC97-L), or highly aggressive HCC cell lines (malignant cells) MHCC97-H was purchased from Type Culture Collection of the Chinese Academy of sciences (Shanghai, P.R. China). Cells were cultured in DMEM (Dulbecco’s Modified Eagle Medium) with 10% fetal bovine serum (FBS). The cDNA samples derived from HCC clinical specimens were gifts from Dr. Fan Feng in No. 302nd hospital, Chinese PLA. The HCC clinical specimens were collected and obtained with the informed consent of patients and with approval for experiments from No. 302nd hospital, Chinese PLA. A total of 52 HCC cases were included (Supplementary Table 1)\textsuperscript{33,34}. Antitumor agents: Betulin was purchased from MCE Corporate (NJ, USA, Cat. No. HY-N0083); Sorafenib was purchased from Selleck Corporation (Houston, TX, USA, Cat. No. S7397). The expression vector of SREBP-1 and SREBP-1 siRNA was purchased from Vigene Corporation, Jinan, China. The siRNA sequence of SREBP-1 is 5’T-GCUCCUCACUU-GAAGGCUUTT-3’. A lentivirus particle of siSREBP-1 was prepared by Vigene Corporation, Jinan, China.

Real-time quantitative PCR
After treating the cells with a series of concentrations of Betulin or Sorafenib (Supplementary Table 2), the RNA samples of the cells were collected and reverse transcribed into cDNA according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). For cDNA samples derived from clinical specimens and cells, quantitative PCR assays were performed according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA) and methods described by Liang et al. and Ji et al.\textsuperscript{35,36}. For primers used in quantitative PCR detection, see Supplementary Table 3.

Western blot experiments
For cell-based experiments, L-02, HepG2, MHCC97-H, MHCC97-L, BEL-7402, SMMC-7721, and Hu7 cells were cultured and harvested after the indicated times. For animal experiments, tumor tissues were harvested and digested. Protein samples were extracted from cells and analyzed for SDS-PAGE. Then, protein samples were trans-printed into PVDF membranes. Next, the membranes were blocked 5% BSA diluted with TBST at 37 °C for 2 h. After blocking, the membranes were in turn incubated by primary antibodies (anti-SREBP-1 antibody [Santa Cruz, USA] or anti-β-Actin antibody [Abcam Corporation, UK]) and the secondary antibody (HRP-coupling antibody, Abcam Corporation, UK). The antibodies of PARP or ki67 were described in our previous work. Membrane exposure was performed in chemiluminescence by using an ECL kit (Amersham Biosciences, Piscataway, NJ, USA)\textsuperscript{37,38}.

MTT assay
After treating HCC cells with the indicated concentrations of agents (Supplementary Table 3), the MTT assay was performed. The amount of HCC cells was determined by the absorbance values of the cell samples at a wavelength of 490 nm. On this basis, the inhibition rate of the drug action was calculated by the OD values. The calculation formula of the inhibition rate is (absorbance value at 490 nm in the control group × 100%)\textsuperscript{41}.

In vitro cell migration and invasion
After the HCC cells were transfected with the expression vectors or treated with the indicated concentration of
agents, the cells were collected for Transwell experiments: the Transwell chamber was pre-plated with ECM glue, and the cells were added to the chamber, fixed for 12–16 h, stained, and photographed. For the obtained photographs, quantitative analysis was performed by using image analysis software Image J42,43. The specific calculation formula is relative invasion/migration cell number = cell total pixel/image total pixel; drug inhibition rate = (control group relative invasion/migration cell number–experiment group)/(control group relative invasion/migration cell number) × 100%.

Metabolic examinations

Metabolic examinations were carried out according to the methods provided by Li et al44,45. Glycolytic activity examinations were performed in either cultured tumor cells or cells isolated from tumors. The glucose uptake (Glucose Uptake Assay Kit (Colorimetric), (ab136955), Abcam), lactate (Lactate-Glo™ Assay Kit, Promega), and ATP (ATP Assay Kit (Colorimetric/Fluorometric) (ab83355), Abcam) production, LDH activity (Lactate Dehydrogenase Activity Assay Kit, Cat#: MAK066, Sigma), extracellular acidification rate (ECAR, Seahorse XF Glycolysis Stress Test Kit, Agilent), and oxygen-consumption rate (OCR, Seahorse XF Cell Mito Stress Test Kit, Agilent) were measured according to the manufacturer’s instructions. On this basis, the inhibition rate was calculated: (control group biochemical index–experimental group biochemical index)/(control group biochemical index) × 100%.

Subcutaneous HCC tumor model

All animal experiments and protocols were approved by the Animal Care and Use Committee of the General hospital, Chinese PLA, and all animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act, 1986 and its associated guidelines. The 4–6-week-old nude mice (Bal B/c mice with T cell/thymus deletion features) were used. HCC cells were cultured, and the cells were injected subcutaneously into nude mice. Then, antitumor agents were intragastrically administered 2–3 days after injection of HCC cells46,47. The concentration gradient of the agents used in the subcutaneous tumor formation experiments is shown in Supplementary Table 4. Animals were intragastrically administered with different concentrations of Betulin, Sorafenib, or Betulin + Sorafenib. The drug was administered once per 2 days, and after 10 times’ treatments (21 days), the animals were killed to collect tumor tissue. The tumor size was calculated and the tumor was weighed. The inhibition rate of the drug acting on the subcutaneous tumor formation of HCC cells was calculated according to tumor size and tumor weight: the inhibition rate calculated based on tumor size [(control tumor size) − (tumor size of the drug treatment group)]/(control tumor size) × 100%; the inhibition rate calculated based on tumor weight [(control tumor weight) − (tumor weight of the drug treatment group)]/(control group tumor weight) × 100%.

Intrahepatic tumor models in nude mice

The collected HCC subcutaneous tumors were prepared into tissue microblocks, and the tissue microblocks were transplanted into the liver of the nude mice48,49. After 2–3 days of tumor transplantation, oral administration of agents was performed, and a solvent control, Betulin or Sorafenib was administered. After 4–6 weeks, the animals were imaged in vivo. Nude mice were inhaled with isoflurane, and the nude mice were injected with 200 μCi (7.4 MBq) of the 18F-FDG radionuclide probe via the tail-vein injection, and the PET testing of animal was performed after about 40–50 min. According to the results of PET, the animal’s anatomy was collected to obtain liver specimens. The specimen was photographed, and the image analysis software Image J was used to analyze the image to determine the relative area of the tumor lesions: [(the total number of pixels in the tumor lesion)/(the total number of pixels in the image)] × 100%; using the Geiger counter to analyze the intensity of the specimen, the liver nuclide intensity is (unit weight of liver organ nuclides)/(unit weight of blood nuclides). The inhibition rate calculated based on the relative area of the tumor lesions [(relative area of tumor lesions in the control group) − (relative area of tumor lesions in the drug treatment group)]/(relative area of tumor lesions in the control group) × 100%; based on tumor weight, the calculated inhibition rate was [(control liver nuclide intensity) − (hepatic nuclide intensity in the drug treatment group)]/(control liver nucleus intensity) × 100%50–52.

Statistical analysis

Statistical analysis was performed by Bonferroni’s correction with or without two-way ANOVA by using SPSS statistical software (IBM Corporation, Armonk, NY, USA). The IC50 and EC50 value of each agent was calculated by the Origin (Origin 6.1; OriginLab Corporation, Northampton, MA, USA). A P-value of <0.05 was considered statistically significant.

Results

SREBP-1 level negatively correlates to the prognosis of HCC patients

The expression of SREBP-1 in 52 fine-needle aspiration tumor specimens derived from HCC patients who received Sorafenib treatment was measured and analyzed. Then these patients were divided into two groups.
according to the median value of the SREBP-1 expression: high and low SREBP-1 groups (Fig. 1a, b). After analysis, we found that the prognosis of patients with low SREBP-1 levels was better than that of patients with high SREBP-1 levels (Fig. 1c, d). The time to progression (TTP) and the overall survival (OS) time of the high SREBP-1 group were shorter compared with those of the low SREBP-1 group (Table 1), suggesting that SREBP-1 negatively correlates to HCC treatment outcomes. In addition, we found that the level of SREBP-1 in HCC cells was significantly higher than that of L-02 nonmalignant liver cells (Fig. 1e, f). High aggressive MHCC97-H cells have the highest SREBP-1 expression among the tested HCC cell lines, suggesting that SREBP-1 correlates with a higher metastatic capacity.

**SREBP-1 promotes HCC cell proliferation and metastasis**

We further tested the role of SREBP-1 in the proliferation and metastasis of HCC cells. Knockdown of SREBP-1 expression in MHCC97-H cells led to an inhibited proliferation and metastasis (Supplementary
Table 1 SREBP-1 expression and outcome of sorafenib treatment

|                      | SREBP-1 mRNA expression | P     |
|----------------------|-------------------------|-------|
|                      | High (n = 27)           | Low (n = 25) |
| TTP                  | 9.1                     | 11.8  | 0.012 |
| OS                   | 11.3                    | 13.7  | 0.024 |
| Overall response rate (CR + PR) | 1 (3.7%)               | 3 (12%) |
| Disease control rate (CR + PR + SD) | 5 (18.5%)             | 8 (32%) |

TTP time to progress, OS overall survival, PR partial remission, CR complete remission, SD stable disease, M months

Knockdown or inhibition of SREBP-1 thwarts the glycolytic activity of HCC cells

Next, we tested the role of SREBP-1 in the regulation of glycolytic activity of HCC cells. Knockdown of SREBP-1 by siRNA decreased glucose uptake and lactate dehydrogenase (LDH) activity in MHCC97-H cells (Supplementary Fig. 4A, B), suggesting that SREBP-1 downregulation impairs anaerobic glycolytic activity. Accordingly, reduced ATP and lactate productions were found upon SREBP-1 knockdown (Supplementary Fig. 4C, D). Moreover, in the SREBP-1-overexpressed MHCC97-L cells, we detected higher glucose uptake, increased LDH activity, and more lactate and ATP production (Supplementary Fig. 4E–H). Next, the glycolysis stress test showed that the SREBP-1 knockdown results in the decreased extracellular acidification rate (ECAR), indicating a lower overall glycolytic activity (Fig. 2a).

Similarly, SREBP-1 overexpression induced a higher ECAR in MHCC97-L cells (Fig. 2b), suggesting the regulatory role of SREBP-1 on HCC cell glycolysis. As an opposite oxidative phosphorylation activity is often observed upon alterations of glycolysis occurrence in tumor cells, which was also termed as the Warburg effect, we performed mitochondrial respiration tests for the oxygen-consumption rate (OCR) measurement. Our results showed increased OCR in SREBP-1 knockdown, whereas decreased OCR in SREBP-1 overexpression groups (Fig. 2c, d). Administration of the SREBP-1 inhibitor Betulin on MHCC97-H cells showed the similar effects, compared with the SREBP-1 knockdown, on lactate and ATP production, and glycolytic activity (Supplementary Fig. 5). Taken together, these data suggest that knockdown or inhibition of SREBP-1 dampens the glucose uptake, anaerobic glycolytic activity, and ATP production of HCC cells.

By testing the transcription level of the key genes in metabolism pathways, we found that Betulin treatment reduced the expression of lipid metabolism-associated genes, including acetyl-CoA carboxylation (ACC), ATP citrate lyase (ACLY), fatty acid synthase (FASN), and acyl-CoA synthetase (ACS) as expected (Fig. 2e, Supplementary Fig. 6 and Supplementary Table 5). For glucose metabolism, glucose uptake, and hypoxia stress, we found decreased expression of GLUT1, LDHA, HIF-1α, and EPAS-1 genes, which is in line with our discovery in the present work. Moreover, given that an abnormal Warburg effect in malignant cells may alter the EMT, which induces the resistance of HCC cells to antitumor chemotherapies, we tested EMT marker genes Twist, Snail, N-cadherin, and Vimentin, and found that they were downregulated after Betulin treatment, indicating a correlation between SREBP-1 and chemoresistance.

SREBP-1 enhances the sensitivity of HCC cells to Sorafenib

To study the role of SREBP-1 in chemoresistance, we performed SREBP-1 overexpression, knockdown, or inhibition in HCC cells in the presence of Sorafenib treatment. Silence of SREBP-1 in MHCC97-H cells enhanced the cytotoxic effect of Sorafenib; the IC₅₀ value decreased from 0.57 ± 0.07 to 0.12 ± 0.01 μmol/L (Fig. 3a). The resistance index (RI) was 4.97. On the other hand, overexpression of SREBP-1 in MHCC97-L cells resisted better to Sorafenib; the IC₅₀ values increased from 0.78 ± 0.04 to 3.33 ± 0.23 μmol/L (Fig. 3b). Similarly, SREBP-1 knockdown synergized the effect of Sorafenib on cell metastasis (Supplementary Fig. 7). Moreover, Betulin administration augmented the killing effect of Sorafenib on MHCC97-H cells, with a decline of IC₅₀ from 0.58 ± 0.06 to 0.15 ± 0.02 μmol/L (Fig. 3c), and facilitated Sorafenib-mediated suppression on metastasis (Fig. 3d). These in vitro data indicate that SREBP-1 induces...
Sorafenib resistance in HCC cells, suggesting the inhibition of SREBP-1 as a strategy to overcome chemoresistance.

**Betulin facilitates Sorafenib’s antitumor effect on s.c. HCC tumors**

We next examined the effect of SREBP-1 inhibition on Sorafenib’s effects in vivo. We first found that Betulin oral gavage administration significantly suppressed s.c. MHCC97-H tumor growth (Supplementary Fig. 8). Gene expression analysis showed that Betulin treatment decreased glucose uptake, LDH activity, and lactate and ATP production in tumor cells in a dose-dependent manner (Supplementary Fig. 9A, B). Furthermore, gene expression analysis of isolated tumor cells showed that Betulin treatment reduced fatty acid and glucose metabolisms and EMT in tumors (Supplementary Fig. 9C and Supplementary Table 6). In order to test whether Betulin works synergistically with Sorafenib on HCC tumors, we administered Betulin at 2 mg/kg, the mild concentration which did not have an obvious tumor rejection effect but had SREBP-1 inhibition activity, in the following experiments.
When combined with Sorafenib, Betulin significantly enhanced the growth of MHCC97-H cells in s.c. tumors, compared with Sorafenib treatment (Fig. 4). This result suggests that Betulin and Sorafenib synergistically reject HCC tumors. We next examined the specificity of Betulin on promoting Sorafenib’s antitumor effect in vivo. We administered HCC s.c. tumors with SREBP-1 siRNA during Sorafenib or Sorafenib and Betulin combination treatments, and found that Betulin could not further control the growth of SREBP-1 knockdown tumors (Fig. 5a, b). However, the effect induced by SREBP-1 knockdown was rescued by ectopic expression of a mutated form of SREBP-1 (SREBP-1mut), which cannot be targeted by the siRNA (Fig. 5a, b). On the other hand, SREBP-1-overexpressed HCC tumors resisted to Sorafenib treatment, but were susceptible to Sorafenib and Betulin combinations (Supplementary Fig. 10A, B). These observations suggest that Betulin facilitates Sorafenib’s effect through SREBP-1 inhibition specifically. Sorafenib induces tumor regression through tumor cell apoptosis. Thus, we tested the level of pro-PARP, cleaved-PARP, and Ki67 in s.c. tumors treated as described above. We found that the knockdown of SREBP-1 promoted apoptosis and restricted cell proliferation, whereas SREBP-1 overexpression reduced cell apoptosis (Fig. 5c and Supplementary Fig. 10C).

Betulin improves Sorafenib-mediated blockade of HCC tumor in situ growth

To study the effect of Betulin on in situ HCC tumor growth during Sorafenib treatment, we established in situ HCC tumors in nude mice livers by using MHCC97-H cell implantation. We then performed Sorafenib or Sorafenib plus Betulin treatment every other day 10 times in total and in the endpoint (day 21 post injection) examined tumor burden by PET/CT scanning. The analysis of the imaging results indicated that Betulin enhanced the effect of Sorafenib upon blocking HCC in situ growth (Fig. 6a–c). Meanwhile, we collected liver tissues and measured tumor lesions (Fig. 6d). Our data showed that the tumor nodule areas of Betulin- and Sorafenib-treated mice were smaller than those of Sorafenib-treated or control mice.
These results indicate that Betulin synergizes Sorafenib in blocking HCC in situ growth, which supports our findings in HCC s.c. tumor treatments. To further study the specificity of Betulin, we performed Sorafenib or Sorafenib plus Betulin treatment upon SREBP-1 knockdown or SREBP-1 overexpressing HCC in situ tumor-bearing mice. We found that SREBP-1 knockdown diminished the effect of Betulin upon synergizing Sorafenib (Supplementary Fig. 11), whereas Betulin exerted a considerable synergistic effect upon treating SREBP-1-overexpressing tumors (Supplementary Fig. 12). These results suggested that Betulin synergizes Sorafenib’s effect upon controlling in situ HCC tumors by targeting SREBP-1.

**Discussion**

Tumors are characterized by intensive anaerobic glycolysis, which benefits tumor cells via providing quick energy for cell proliferation, altering the hostile tumor microenvironment for immune cell infiltration, and inducing drug resistance. Therefore, targeting glucose metabolism-related pathways is considered as an effective approach to control tumor growth and enhance the efficacy of antitumor chemotherapy. SREBP-1 is one of the major regulators of cellular lipid metabolism; it controls lipid synthesis via transcriptional regulation of its downstream genes: FASN, ACC, ACLY, SCD, and so on. Due to the close correlation of glucose and lipid metabolisms, SREBP-1 is also known to regulate glucose
and glutamine metabolic pathways. Betulin can inhibit SREBP family protein activation by directly binding to the SCAP region of this molecule which further blocks the cleavage of SREBP. Li et al. have reported that inhibiting SREBPs by Betulin can suppress HCC tumor-associated inflammation. Inflammation in tumors, specifically induced by chronic viral infection, is critical for tumor-associated immune suppression and drug resistance. Thus, we hypothesized that Betulin treatment on HCC tumor models can induce tumor regression and reduce drug resistance against chemotherapy. In the present study, we showed that a high level of SREBP-1 correlates with poor prognosis of HCC patients treated with the chemotherapy agent Sorafenib. Our study provides evidence that SREBP-1 protects the tumor cell via enhancing glycolytic activities and SREBP-1 inhibition induces cell death and promotes the antitumor effect of Sorafenib. These results indicated that SREBP-1 is critical for HCC tumor development and targeting to SREBP-1 is therapeutically effective for HCC treatment.

The Warburg effect is characterized by the transformation of the energy acquisition from oxidative phosphorylation to anaerobic glycolysis, which is regarded as a hallmark of tumor cells. Intracellular glucose can be hydrolyzed into pyruvate during glycolysis; then pyruvate goes into the tricarboxylic acid cycle when the oxygen supply is sufficient and energy demand is low. However, in the hypoxic tumor microenvironment, where energy demand is very high, pyruvate is metabolized into lactate acid via anaerobic glycolysis, and glucose uptake is enhanced to increase the ATP production in tumor cells. To block glycolytic activity during HCC treatment, there are three strategies: (1) using inhibitors of glucose transporters, (2) using inhibitors targeting hypoxia-associated pathways, and (3) inhibitors of LDHA to ameliorate the accumulation of lactic acid. Hypersynthesis of fatty acid in HCC cells is driving glucose uptake. Inhibition of SREBP-1 represses lipid metabolism in tumor cells, and in turn inhibits glucose uptake and glycolysis. In this study, we showed that knockdown or inhibition of SREBP-1 in HCC cells impaired glucose uptake, LDH activity, and reduced ATP and lactate production, which provide mechanistic insights into the SREBP-1 function.

As a primary therapeutic choice of HCC treatment, Sorafenib does not deliver a robust effect due to the subsequent resistance that occurs soon after the initial treatment. It has been reported that inhibition of lipid metabolism effectively represses the growth and metastasis of tumor cells and reduces Sorafenib resistance. Thus, the inhibition of cellular metabolism which facilitate tumor cell survival may enhance the efficacy of therapeutic chemodrugs. Our results indicated that Betulin as the SREBP-1 inhibitor overcomes the resistance of HCC cells to Sorafenib. Further studies will attempt to address two aspects: first, study the mechanism by which Betulin-treated cells or SREBP-1 knockdown cells become less resistant to Sorafenib; second, prove the accessibility that SREBP-1 becomes a prognosis marker of HCC patients.

Fig. 5 SREBP-1 knockdown synergizes Sorafenib’s effect on HCC s.c. tumor growth. a MHCC97-H s.c. tumors were established by using MHCC97-H cells transfected with control or SREBP-1 siRNAs, or SREBP-1 siRNAs plus SREBP-1α controls expressing vector. MHCC97-H s.c. tumor-bearing mice received vehicle control, or Sorafenib at the IC50 concentration, or 2 mg/kg Betulin or Sorafenib + Betulin orally every other day 10 times. At day 21 post treatment, mice were killed and tumors were obtained (N = 10). b Quantitative results of tumor volume and tumor weight from a. c Western blotting of SREBP-1 and apoptosis and proliferation-associated proteins in tumors from a. β-actin was used as internal control.
Fig. 6 (See legend on next page.)
Fig. 6 Betulin synergizes Sorafenib's effect on HCC in situ growth in the mouse liver. a The in situ xenograft tumors were established by injected MHCC97-H cells directly into mouse livers. Tumor-bearing mice then received vehicle control, or the indicated concentrations of Sorafenib, or 2 mg/kg Betulin or the indicated concentration of Sorafenib + 2 mg/kg Betulin orally every other day 10 times. At day 21 post treatment, mice were scanned by in vivo small-animal MicroPET imaging (N = 10). The images show the in situ tumors. b The 18F-FDG intensity analysis and quantification results. c Relative inhibitory rate of tumor growth calculated from (b). d Livers from control or tumor-bearing mice from a e Representative tumor nodules from each treatment group. f Quantification results from e

Acknowledgements
This work is supported by Translational Medicine Program of Chinese PLA General Hospital internal grant (2017TM-022) for F.Y.

Author details
1. Department of Oncology, the Second Medical Centre & National Clinical Research Center of Geriatric Disease, Chinese PLA General Hospital, 100853 Beijing, People’s Republic of China. 2. Center for Clinical Laboratory, the Fifth Medical Centre, Chinese PLA General Hospital, 100039 Beijing, People’s Republic of China. 3. Department of Gastroenterology, the First Medical Centre, Medical Centre, Chinese PLA General Hospital, 100039 Beijing, People’s Republic of China. 4. Department of Blood Transfusion, the First Hospital of Jilin University, Changchun 130021 Jilin Province, People’s Republic of China. 5. Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, 33612 Tampa, FL, USA.

Author contributions
Y.C. conceived the main ideas and wrote the paper; Y.C. and F.Y. supervised the study; F.Y. F.F., and L.W. developed major methodologies, databases, reagents, and primary experiments; X.W. and Z.L. analyzed different aspects of the results.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41419-019-1884-7).

Received: 1 July 2019 Revised: 20 August 2019 Accepted: 26 August 2019

Published online: 11 September 2019

References
1. Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. 3, 383–403 (2018).
2. Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect. Dis. 16, 1399–1408 (2016).
3. Zhang, S., Wang, F. & Zhang, Z. Current advances in the elimination of hepatitis B in China by 2030. Front. Med. 11, 490–501 (2017).
4. Yang, F. et al. The global burden of liver disease: the major impact of China. Hepatology 60, 2099–2110 (2014).
5. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
6. Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314 (2018).
7. Kudoh, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018).
8. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).
9. Roskoski, R. Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol. Res. 144, 19–50 (2019).
10. Lacal, P. M. & Graziani, G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol. Res. 136, 97–107 (2018).
11. Roskoski, R. Jr. Targeting oncogenic Ras protein-serine/threonine kinases in human cancers. Pharmacol. Res. 135, 239–258 (2018).
12. Llovet, J. M. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
13. Cheng, A. L. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
14. Roskoski, R. Jr. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacol. Res. 133, 35–52 (2018).
15. Roskoski, R. Jr. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacol. Res. 129, 65–83 (2018).
16. Zhu, Y. J. et al. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol. Sin. 38, 614–622 (2017).
17. Feng, F. et al. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol. Res. 135, 89–101 (2018).
18. Shen, Y. et al. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signalling pathways. Onco Targets Ther. 12, 5009–5012 (2019).
19. Huang, X. et al. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 15, 1258–1279 (2019).
20. Zhang, Q. et al. Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect. Cell Death Dis. 10, 43–59 (2019).
21. Chen, Z. et al. MR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect. Cell Death Dis. 9, 549–562 (2018).
22. Zhang, L. F. et al. Suppression of miR-199a maturation by HURe is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma. Environ. Mol. Mutagen. 83, 1279–1285 (2018).
23. Lu, F. et al. Hox kinase II promotes the Warburg effect by phosphorylating alpha subunit of pyruvate dehydrogenase. Chin. J. Cancer Res. 31, 521–532 (2019).
24. Berthier, A. et al. Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERsβ complex. Proc. Natl Acad. Sci. USA 115, E1039–E1104 (2018).
25. Yang, X. et al. GPR73 regulates Hepatic Steatosis by enhancing SCAP-SREBP1c interaction. Sci. Rep. 7, 14932 (2017).
26. Wu, H. et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBPI-p53-Srebplc pathway. Gut 65, 1850–1860 (2016).
27. Liu, L. et al. Arginine methylation of SREBP1c by PRMT5 promotes de novo-lipogenesis and tumor growth. Cancer Res. 76, 1266–1272 (2016).
28. Park, S. et al. Expeditious synthesis of aliphatic acid and its naturally occurring 2-0-ester derivatives. J. Nat. Prod. 82, 895–902 (2019).
29. Xu, G. M. et al. Betulin inhibits lipopolysaccharide/d-galactosamine-induced acute liver injury in mice through activating PPAR-γ. Biomed. Pharmacother. 106, 941–945 (2018).
30. Kanhar, S. & Sahoo, A. K. & Mahapatra, A. K. The ameliorative effect of homalium nepalense on carbon tetrachloride-induced hepatic cellular injury in rats. Biomed. Pharmacother. 103, 903–914 (2018).
31. Tang, J. J. et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44–56 (2011).
32. Shimano, H. et al. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98, 1575–1584 (1996).
33. Shao, Z. et al. ET-51 induces sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res. 135, 188–200 (2018).
34. Feng, F. et al. Pregnan X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim. Biophys. Acta Gen. Subj. 1862, 1017–1030 (2019).
35. J. J. et al. miR-216a inhibits osteosarcoma cell proliferation, invasion and metasasis by targeting CDK14. Cell Death Dis. 8, e3103 (2017).
36. Liang, Y. et al. The ECRG/miR-338-3p/AY24 axis controls breast tumor growth and lung metastasis. Cell Death Dis. 8, e2928 (2017).
37. Wang, L. et al. Aminophenols increase proliferation of thyroid tumor cells by inducing the transcription factor activity of estrogen receptor α. Biomed. Pharmacother. 109, 62–69 (2018).
38. Fan, Z. et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cancer Lett. 450, 132–143 (2019).
39. Li, J. et al. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Oncol. Targets Ther. 11, 5885–5894 (2018).
40. Li, F. et al. Pps2p3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron. Cell Death Dis. 9, 1025 (2018).
41. Guan, F. et al. Wx-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects. Oncotarget 8, 71782–71796 (2017).
42. Ingersoll, M. A. et al. p65hc regulates migration of castration-resistant prostate cancer cells. Cell Signal. 46, 1–14 (2018).
43. Zheng, B. et al. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PI3K-AKT-NFκB axis. Cell Signal. 45, 122–131 (2018).
44. Li, L. et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDLA-mediated Warburg effect. Cancer Lett. 400, 89–98 (2017).
45. Li, L. et al. Transcriptional regulation of the warburg effect in cancer by SIRT6 via FRML1/FOXO3a inhibits the Warburg effect in glioblastoma cells. Cell Signal. 60, 100–113 (2019).
46. Yang, W. et al. Knockdown of cZNF292 suppressed hypoxic human hepatoma SMMC7721 cell proliferation, vasculogenic mimicry, and radioresistance. Cell Signal. 60, 122–135 (2019).
47. Hu, Z. et al. FOXO3a-dependent up-regulation of Mek1-0 promotes hypoxia-induced apoptosis in endothelial cells. Cell Signal. 51, 233–242 (2018).
48. Li, L. et al. Identification and functional characterization of Lys-trimethylation of lactate dehydrogenase A. Onco Targets Ther. 12, 5395–5409 (2019).
49. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519–1523 (2011).
50. Tennant, D. A., Duran, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10, 267–277 (2010).
51. Li, C. et al. SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int. J. Mol. Sci. 15, 7124–7138 (2014).
52. Soum, N. E. et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20, 280–294 (2014).
53. Sqqingaowa et al. Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation. Biochem. Biophys. Res. Commun. 488, 136–140 (2017).
54. Meyer, T. et al. Sorafenib in combination with trastuzumab chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 565–575 (2017).